As of 2024-12-11, the EV/EBITDA ratio of Aclaris Therapeutics Inc (ACRS) is -6.65. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Aclaris's latest enterprise value is 211.64 mil USD. Aclaris's TTM EBITDA according to its financial statements is -31.85 mil USD. Dividing these 2 quantities gives us the above Aclaris EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.6x - 10.0x | 8.6x |
| Forward P/E multiples | 13.2x - 19.2x | 16.6x |
| Fair Price | (5.22) - (3.79) | (4.95) |
| Upside | -243.7% - -204.4% | -236.4% |
| Date | EV/EBITDA |
| 2024-12-04 | -6.94 |
| 2024-12-03 | -7.13 |
| 2024-12-02 | -7.39 |
| 2024-11-29 | -7.63 |
| 2024-11-27 | -7.07 |
| 2024-11-26 | -6.65 |
| 2024-11-25 | -7.45 |
| 2024-11-22 | -7.03 |
| 2024-11-21 | -8.19 |
| 2024-11-20 | -7.39 |
| 2024-11-19 | -8.80 |
| 2024-11-18 | -5.55 |
| 2024-11-15 | -3.10 |
| 2024-11-14 | -3.39 |
| 2024-11-13 | -3.98 |
| 2024-11-12 | -4.25 |
| 2024-11-11 | -4.40 |
| 2024-11-08 | -4.43 |
| 2024-11-07 | -4.00 |
| 2024-11-06 | -3.57 |
| 2024-11-05 | -3.48 |
| 2024-11-04 | -3.37 |
| 2024-11-01 | -3.19 |
| 2024-10-31 | -2.56 |
| 2024-10-30 | -2.54 |
| 2024-10-29 | -2.34 |
| 2024-10-28 | -2.11 |
| 2024-10-25 | -2.29 |
| 2024-10-24 | -1.40 |
| 2024-10-23 | -1.33 |
| 2024-10-22 | -1.35 |
| 2024-10-21 | -1.22 |
| 2024-10-18 | -1.17 |
| 2024-10-17 | -1.13 |
| 2024-10-16 | -1.11 |
| 2024-10-15 | -1.15 |
| 2024-10-14 | -1.20 |
| 2024-10-11 | -1.15 |
| 2024-10-10 | -1.11 |
| 2024-10-09 | -1.13 |
| 2024-10-08 | -1.11 |
| 2024-10-07 | -1.08 |
| 2024-10-04 | -1.17 |
| 2024-10-03 | -1.17 |
| 2024-10-02 | -1.13 |
| 2024-10-01 | -1.15 |
| 2024-09-30 | -1.08 |
| 2024-09-27 | -1.13 |
| 2024-09-26 | -1.15 |
| 2024-09-25 | -1.02 |